Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Doxorubicin and Carboplatin in TNBC
NCT02315196Phase 2Active, not recruiting
- Sponsor
- Rutgers University
- Start
- Feb 2015
- Primary completion
- Feb 2021
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin, carboplatin in triple-negative breast cancer (TNBC), sponsored by Rutgers University. Started Feb 2015; status: active, not recruiting.
02
Drugs
pegylated liposomal doxorubicincarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02315196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315196.